Treatment for anemia in people with AIDS

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Martí Carvajal, Arturo José ^a   Sola I ^b  

^a Centro Colaborador Venezolano de la Red Cochrane Iberoamericana   (Venezuela)

^b NONE

Author keywords

Acquired immunodeficiency syndrome *complications ; Anemia *therapy ; Erythropoietin, recombinant *therapeutic use ; Humans; Randomized controlled trials as topic

Indexed keywords

DIDANOSINE; FERROUS SULFATE; FOLIC ACID; PENTAMIDINE; RECOMBINANT ERYTHROPOIETIN; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ANEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; NAUSEA; PAIN; PROGNOSIS; QUALITY OF LIFE; REVIEW; SEIZURE; SYSTEMATIC REVIEW; URTICARIA;

EID: 44049101344     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004776.pub2     Document Type: Review

References (94)

1. Fischl 1990 {published data only} Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH Kennedy P, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine.[comment]. New England Journal of Medicine 1990;332:1488-93.
2. Grossman 2003 {published data only} Grossman HA, Goon B, Bowers P, Leitz G. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003;34:368-78.
3. Rendo 2001 {published data only} Rendo P, Freigeiro D, Barboni G, Donato H, Drelichman G, Gonzalez F. A multicenter, randomized, double-blind trial with recombinant human erythropoietin (rHuEPO) in anemic HIV-infected children treated with antiretrovirals. International Journal of Pediatric Hematology/Oncology 2001;7:235-9.
4. Sulkowski 2005 {published data only} Sulkowski MS, Dieterich DT, Bini EJ, Brau N, Alvarez D, DeJesus E, et al. Epoetin alfa once weekly improves anemia in HIV/Hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. Journal of Acquired Immune Deficiency Syndromes 2005;39:504-6.
5. Abrams 2000 Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. International Journal of STD & AIDS 2000;11:659-65.
6. Accetturi 1995 Accetturi CA, Suleiman J, Turcato Jr G, Suleiman G, Lewi DS. An open clinical trial with recombinant human erythropoietin (rHuEPO) in the management of anemia associated with acquired immunodeficiency syndrome under zidovudine therapy [ESTUDO CLINICO ABERTO COM ERITROPOIETINA HUMANA RECOMBINANTE (R-HUEPO) NO TRATAMENTO DA ANEMIA ASSOCIADA A INFECCAO PELO VIRUS DA IMUNODEFICIENCIA HUMANA E AO TRATAMENTO COM AZIDOTIMIDINA (AZT)]. Arquivos Brasileiros de Medicina 1995;69(3):151-4.
7. Adamson 1990 Adamson JW, Eschbach JW. The use of recombinant human erythropoietin (rHuEpo) in humans. Cancer Surveys 1990;9(1):157- 67.
8. Anonymous 1996 Anonymous. Erythropoietin enhances quality of life in HIV-infected persons. P and T 1996;21:504.
9. Belperio 2004 Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: A systematic review of the literature. American Journal of Medicine 2004;116(7A):27S-43S.
10. Berhane 2004 Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. Journal of Acquired Immune Deficiency Syndromes 2004;37:1245-52.
11. Brokering 2003 Brokering KL, Qaqish RB. Management of anemia of chronic disease in patients with the human immunodeficiency virus. Pharmacotherapy 2003;23:1475-85.
12. Buskin 2004 Buskin SE, Sullivan PS. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion 2004;44:826-32.
13. Caselli 1996 Caselli D, Maccabruni A, Zuccotti GV, Riva E, Fundaro C, Portelli V, et al. Recombinant erythropoietin for treatment of anemia in HIV infected children. AIDS 1996;10:929-31.
14. Garnick 1991 Garnick MB, Abels R, Rudnick SA. The role of recombinant human erythropoietin in the management of anemia associated with acquired immnunodeficiency syndrome. Erythropoietin in renal and non-renal anemias. Karger, 1991.
15. Hanna 1998 Hanna L. Epoietin alfa (EPO) for anemia. BETA 1998:40-2.
16. Henry 1990 Henry DH. Erythropoietin therapy in AIDS. Progress in Clinical & Biological Research 1990;338:113-20.
17. Henry 1992 Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.[comment]. Annals of Internal Medicine 1992;117:739-48.
18. Henry 1998 Henry DH. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia. Seminars in Oncology 1998;25 (Suppl 7):64-8.
19. Henry 2004 Henry DH, Volberding PA, Leitz G. Epoetin alfa for treatment of anemia in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2004;37:1221-7.
20. Jacobson 1990 Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion 1990;30(2):133-7.
21. Krantz 1995 Krantz SB. Erythropoietin and the anaemia of chronic disease. Nephrology Dialysis Transplantation 1995;10(Suppl 2):10-7.
22. Lancaster 1993 Lancaster DJ, Palte S, Ray D. Recombinant human erythropoietin in the treatment of anemia in AIDS patients receiving concomitant amphotericin B and zidovudine. Journal of Acquired Immune Deficiency Syndromes 1993;6:533-4.
23. Levine 2003 Levine AM. Anemia in the setting of cancer and human immunodeficiency virus. Clinical Infectious Disease 2003;37(Suppl 4):S304-14.
24. Mueller 1994 Mueller BU, Jacobsen F, Jaronski P, Lewis LL, Pizzo PA. Erythropoietin for zidovudine-associated anemia in children with HIV infection. Pediatric AIDS and HIV infection: Fetus to Adolescent 1994;5:169-73.
25. Revicki 1994 Revicki DA, Brown RE, Henry DH, McNeill MV, Rios A, Watson T. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. Journal of Acquired Immune Deficiency Syndromes 1994;7:474-84.
26. Saag 2004 Saag MS, Bowers P, Leitz GJ, Levine AM, et al. Once-Weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV + patients. AIDS Research and Human Retroviruses 2004;20:1037-45.
27. Sullivan 2002 Sullivan P. Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 2002;185 Suppl 2:S138-42.
28. Volberding 2000 Volberding P. Consensus statement: anemia in HIV infection-current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clinical Therapeutics 2000;22:1004-9.
29. Volberding 2002 Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 2002;185 Suppl 2:S110-4.
30. Volberding 2004 Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical Infectious Diseases 2004;38:1454-63.
31. Walker 1988 Walker RE, Parker RI, Kovacs JA, Masur H, Lane HC, Carleton S. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Annals of Internal Medicine 1988;108:372-6.
32. NCT00246298 2006 A Randomized, Open-Label Study Assessing the Efficacy of Initiating PROCRIT® (Epoetin Alfa) Dosing at Q2W Vs. PROCRIT® Dosing at QW in Anemic HIV-Infected Subjects.. Ongoing study January 2005.
33. Afacan 2002 Afacan YE, Hasan MS, Omene JA. Iron deficiency anemia in HIV infection: immunologic and virologic response. Journal of the National Medical Association 2002;94:73-7.
34. AHQR 2003 AHQR. HIV-related hematologic manifestations in pediatrics. 2003. http://www.guideline.gov/summary/summary.aspx?ss= 15&doc_id=3808&nbr=3034 [Accessed October 12, 2005].
35. Angell 2004 Angell M. Excess in the pharmaceutical industry. Canadian Medical Association journal 2004;171:1451-3.
36. Beyan 2005 Beyan C, Beyan E. A common cause of anemia in inflammatory disorders: Anemia of chronic disease. Current Rheumatology Reviews 2005;1:227-30.
37. Bhandari 2004 Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association journal 2004;170:477-80.
38. Bieber 2001 Bieber E. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. Journal of Reproductive Medicine for the Obstetrician and Gynecologist 2001;46(5 Suppl):521-530.
39. Bozzi 2004 Bozzi A, Brisdelli F, D'Alessandro AM, D'Andrea G, Lizzi AR, Rinaldi AC, et al. Effects of AZT on cellular iron homeostasis. Biometals 2004;17:443-50.
40. Butensky 2004 Butensky E, Kennedy CM, Lee MM, Harmatz P, Miaskowski C. Potential mechanisms for altered iron metabolism in human immunodeficiency virus disease. The Journal of the Association of Nurses in AIDS Care 2004;15:31-45.
41. Camacho 1992 Camacho J, Poveda F, Zamorano AF, Valencia ME, Vazquez JJ, Arnalich F. Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection. British Journal of Haematology 1992;82:608-14.
42. CDC 1993 Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. http://www.cdc.gov/mmwr/ preview/mmwrhtml/00018871.htm.
43. Clark 2001 Clark TD, Semba RD. Iron supplementation during human immunodeficiency virus infection: a double-edged sword?. Medical hypotheses 2001;57:476-9.
44. Claster 2002 Claster S. Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection. The Journal of Infectious Diseases 2002;185(Suppl 2):S105-S109.
45. Cotter 2004 Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodyalisis patients. Journal of Clinical Epidemiology 2004;57:1086-95.
46. Cunningham 2005 Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. The Journal of allergy and clinical immunology 2005;115:1119-28.
47. D'Alessandro 2000 D'Alessandro AM, Rinaldi AC, D'Andrea G, Brisdelli F, Di Ciccio L, Di Giulio A, et al. Evidences that zidovudine (AZT) could not be directly responsible for iron overload in AZT-treated patients: an in vitro study. Clinica chimica acta 2000;300:119-30.
48. Davila-Hicks 2004 Davila-Hicks P, Theil EC, Lonnerdal B. Iron in ferritin or in salts (ferrous sulfate) is equally bioavailable in nonanemic women. American Journal of Clinical Nutrition 2004;80:936-40.
49. Domellöf 2002 Domellöf M, Hernell O. Iron-deficiency anaemia during the first two years of life. Scandinavian Journal of Nutrition 2002;46:20-30.
50. Elbim 2001 Elbim C, Pillet S, Prevost MH, Preira A, Girard PM, Rogine N, et al. The role of phagocytes in HIV-related oxidative stress. Journal of Clinical Virology 2001;20:99-109.
51. Evans et al 2000 Evans RH, Scadden DT. Haematological aspects of HIV infection. Baillére' s Clinical Hematology 2000;13(2):215-30.
52. Fergusson 2002 Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. British Medical Journal 2002;325:652-4.
53. Fitzsimons 2002 Fitzsimons EJ, Sturrock RD. The chronic anaemia of rheumatoid arthritis: iron banking or blocking?. Lancet 2002;360:1713-4.
54. Flament 1986 Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem JL. Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clinical Nephrology 1986;25:227-30.
55. Gabrilove 2000 Gabrilove 2000. Overview: Erythropoiesis, anemia, and the impact of erythropoietin. Seminars in Hematology 2000;37(Suppl 6)(4):1-3.
56. Gordeuk 2001 Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR. Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001;20(3):111-5.
57. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:557-60.
58. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd, 2005.
59. Ibbotson et al 2001 Ibbotson T, Goa KL. Darbepoetin Alfa. Drugs 2001;61(14):2097-104.
60. Joy 2002 Joy MS. Darbepoetin Alfa: A novel erythropoiesis -stimulating protein. Annals of Pharmacotherapy 2002;36:1183-92.
61. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323:42-6.
62. Koury 2004 Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annual Review of Nutrition 2004;24:105-31.
63. Kreuzer et al 1997 Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. Annals of Hematology 1997;75:179-87.
64. Lewis 2005 Lewis DK, Whitty CJ, Walsh AL, Epino H, Broek NR, Letsky EA, et al. Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005;99:561-7.
65. Lexchin 2003 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326:1167-70.
66. Lexchin 2005 Lexchin JR. Implications of pharmaceutical industry funding on clinical research. The Annals of Pharmacotherapy 2005;39:194-7.
67. Macdougall 2005 Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. European Journal of Clinical Investigation 2005;35 (Suppl. 3):32-5.
68. Melander 2003 Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal 2003;326:1171-3.
69. Mocroft 1999 Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999;13:943-50.
70. Moore 1998 Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;19:29-33.
71. Moore 2002 Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2002;29:54-7.
72. Moyle 2002 Moyle G. Anaemia in persons with HIV infection: Prognostic marker and contributor to morbidity. AIDS reviews 2002;4:13-20.
73. Moylett et al 2002 Moylett EH, Shearer WT. HIV: clinical manifestations. Journal of Allergy and Clinical Immunology 2002;110:3-16.
74. ONUSIDA/OMS 2004 Organización Mundial de la Salud. Situación de la epidemia de SIDA. Organización Mundial de la Salud, 2004.
75. Patruta 1998 Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. Journal of the American Society of Nephrology 1998;9:655-63.
76. Perkins 2003 Perkins L, Hussein G, Leung B. Anemia and erythropoietin (rHuEPO) management program for optimal therapeutics and patient care. Clinical Research and Regulatory Affaire 2003;20:331-9.
77. Phair et al 1993 Phair JP, Abels RI, McNeill MV, Sullivan DJ. Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Archives of Internal Medicine 1993;153:2669-75.
78. Sani 2005 Sani MU, Okeahialam BN, Aliyu SH, Enoch DA. Human immunodeficiency virus (HIV) related heart disease: a review. Wiener klinische Wochenschrift 2005;117:73-81.
79. Semba 2001 Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV infected injection drug users receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001;26:315-9.
80. Sipsas et al 1999 Sipsas NV, Kokori SI, Ionnidis JPA. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1 related anemia. Journal of Infectious Diseases 1999;180:2044-7.
81. Sloand 2005 Sloand E. Hematologic complications of HIV infection. AIDS reviews 2005;7:187-96.
82. Stocker 2004 Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiological Reviews 2004;84:1381-478.
83. Sullivan 1998 Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998;91:301-8.
84. Taylor 2005 Taylor GJ, Wainwright P. Open label extension studies: research or marketing?. British Medical Journal 2005;331:572-4.
85. Theil 2004 Theil EC. Iron, ferritin, and nutrition. Annual Review of Nutrition 2004;24:327-43.
86. Totin 2002 Totin D, Ndugwa C, Mmiro F, Perry RT, Jackson JB, Semba RD. Iron deficiency anemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda. Journal of Nutrition 2002;132:423-9.
87. Umeh 2005 Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS reports 2005;2:132-9.
88. van den Broek 1998 van den Broek NR, White SA, Neilson JP. The relationship between asymptomatic human immunodeficiency virus infection and the prevalence and severity of anemia in pregnant Malawian women. American Journal of Tropical Medicine and Hygiene 1998;59:1004-7.
89. Volberding 2000 Volberding P for the Anemia in HIV Working Group. Consensus Statement: Anemia in HIV infection-Current trends, treatment options, and pratice strategies. Clinical Therapeutics 2000;22(9):1004-20.
90. Volberding 2004 Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical infectious diseases 2004;38:1454-63.
91. Weiss 2005 Weiss G, Goodnough LT. Anemia of chronic disease. New England Journal of Medicine 2005;352:1011-23.
92. Weiss 2005-B Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anaemias. European Journal of Clinical Investigation (2005) 35 (Suppl. 3), 36-45 2005;35 (Suppl. 3):36-45.
93. WHO 2005 World Health Organization. Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. http://www.who.int/ hiv/pub/guidelines/clinicalstaging.pdf.
94. Zon et al 1988 Zon LI, Groopman J. Hematologic manifestations of the human immune deficiency virus (HIV). Seminars in Hematology 1988;25(3):208-18.